Brief: Alligator Bioscience Gets FDA Authorization To Start Mitazalimab Optimize-2 Phase 2 Trial
03/04/2023 07:36
April 3 (Reuters) - Alligator Bioscience AB ATORX.ST :
* ANNOUNCES FDA AUTHORIZATION TO INITIATE MITAZALIMAB
OPTIMIZE-2
PHASE 2 TRIAL IN UROTHELIAL CARCINOMA
* EXPECTS OPTIMIZE-2 STUDY TO BEGIN IN H1 2024, OR EARLIER,
SUBJECT TO OPERATIONAL FEASIBILITY
Source text for Eikon: ID:nMFN4dmySP
Further company coverage: ATORX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))
Recent news on Alligator Bioscience AB
See all newsBrief: Alligator Bioscience Q1 Net Loss SEK 1.4 Million
Sweden's Alligator Bioscience posts Q1 net profit, narrows operating loss
Brief: Alligator Bioscience Q1 EBIT SEK -17.8 Million
Brief: Alligator Bioscience Signs LoI With Unicancer For Phase 3 Mitazalimab Development
Brief: Exercise Of Warrants Brings Alligator Bioscience Net Proceeds Of SEK 12 Mln